VIDEO: Faricimab shows positive real-world results for wet AMD over 9 months
SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Theodore Leng, MD, FACS, discusses results of the FARETINA-AMD study investigating faricimab for wet age-related macular degeneration.
According to Leng, FARETINA-AMD is the largest ongoing real-world study investigating faricimab and uses data from the IRIS Registry to observe treatment patterns in the first 9 months of the drug’s release.
“I think this speaks to the fact that clinicians like myself that are treating retinal patients every day feel very comfortable with this agent and the mechanism of action and the safety profile that we’ve seen to date,” he said.
Collapse
Leng T. Early treatment patterns and outcomes in patients with neovascular age related macular degeneration initiating faricimab: The FARETINA-AMD study. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Read more about